Bavarian Nordic is a leading industrial biotechnology
company developing and producing novel vaccines for the treatment
and prevention of life-threatening diseases with a large unmet
medical need.
The company's pipeline is focused in
the three areas; biodefence, cancer and infectious diseases, and
includes seven development programmes. Two programmes are ready for
Phase III: IMVAMUNE®, a third-generation smallpox vaccine is
being developed under a contract with the US government, and
PROSTVAC™, a therapeutic vaccine for advanced prostate cancer
is being developed under a collaboration agreement with the
National Cancer Institute.
Bavarian Nordic is listed on NASDAQ OMX
Copenhagen under the symbol BAVA.
